ezetimibe has been researched along with Disease Exacerbation in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (34.04) | 29.6817 |
| 2010's | 28 (59.57) | 24.3611 |
| 2020's | 3 (6.38) | 2.80 |
| Authors | Studies |
|---|---|
| Bang, CN; Boman, K; Egstrup, K; Greve, AM; Kesäniemi, YA; Pedersen, TR; Ray, S; Wachtell, K | 1 |
| Arrese, M; Bizama, C; Espinoza, JA; Ferreccio, C; García, P; Gómez, N; González, X; Guevara, F; Kalergis, AM; Lobos-González, L; Miquel, JF; Muñoz-Durango, N; Roa, JC; Rosa, L; Saavedra, N; Villegas, J; Wichmann, IA | 1 |
| Bahlmann, E; Chambers, JB; Cramariuc, D; Einarsen, E; Gerdts, E; Midtbo, H | 1 |
| Bahlmann, E; Boman, K; De Simone, G; Gerdts, E; Gohlke-Bärwolf, C; Lønnebakken, MT; Rossebø, AB; Saeed, S | 1 |
| Amano, T; Fujiwara, H; Hibi, K; Ishii, H; Kawasaki, M; Kimura, K; Koshida, R; Kozuma, K; Miyamoto, T; Morino, Y; Morita, S; Murohara, T; Otsuji, Y; Ozaki, Y; Sata, M; Sato, K; Sonoda, S | 1 |
| Bang, CN; Best, P; Boman, K; Egstrup, K; Forman, JL; Greve, AM; Kesäniemi, YA; Pedersen, TR; Rajamannan, NM; Ray, S; Wachtell, K | 1 |
| Ahangari, N; Ghayour Mobarhan, M; Pasdar, A; Sahebkar, A | 1 |
| Bang, CN; Boman, K; Eugen-Olsen, J; Forman, JL; Greve, AM; Hodges, GW; Jeppesen, JL; Kesäniemi, YA; Olsen, MH; Ray, S; Wachtell, K | 1 |
| Hattori, E; Hirao, K; Kasano, K; Matsumoto, S; Nakamura, S; Teng, Y; Tokunaga, T; Yamamoto, T; Yonetsu, T; Yoshiwara, H | 1 |
| Gerdts, E; Gohlke-Bärwolf, C; Jander, N; Minners, J; Pedersen, TR; Ray, S; Wachtell, K | 1 |
| Jones, PJ; Myrie, SB; Othman, RA | 1 |
| Asakura, Y; Habara, M; Ito, T; Kimura, M; Kinoshita, Y; Ko, E; Kurita, T; Matsubara, T; Nasu, K; Suzuki, T; Teramoto, T; Terashima, M; Tsuchikane, E; Yokota, D | 1 |
| Barbosa, CP; Bersani-Amado, CA; Cuman, RK; da Silva, LG; Grespan, R; Hernandes, L; Ritter, AM | 1 |
| Jackevicius, CA; Ko, DT; Krumholz, HM; Lu, L; Ross, JS; Tu, JV | 1 |
| Agodoa, L; Baigent, C; Cass, A; Craig, JC; de Zeeuw, D; Emberson, J; Feldt-Rasmussen, B; Fellström, B; Haynes, R; Herrington, WG; Landray, MJ; Levin, A; Lewis, D; Reith, C; Walker, R; Wheeler, DC | 1 |
| Frazee, SG; Garavaglia, SB; Jackevicius, CA; Krumholz, HM; Levin, R; Novshadian, H; Ross, JS; Stettin, G | 1 |
| Basta, N; Bolin, K; Busch-Sørensen, M; Egstrup, K; Emneus, M; Green, A; Iachina, M; Kent, C; Kesäniemi, YA; McNally, R; Pedersen, TR; Ramey, DR; Ray, S; Stavem, K; Willenheimer, R | 1 |
| Baigent, C; Cass, A; Emberson, J; Gray, A; Haynes, R; Herrington, W; Landray, MJ; Mihaylova, B; Morton, RL; Schlackow, I; Staplin, N | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Chen, Z; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Lopez, JJ; Skalicka, H; Sonka, M; Wahle, A; Zhang, L | 1 |
| Shi, L; Wang, J; Wang, X; Yang, L; Zhao, J; Zhao, P | 1 |
| Altmann, SW; Basso, F; Davis, HR; Hoos, LM; Lally, SM; Tetzloff, G | 1 |
| Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
| Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Nienaber, CA; Pedersen, TR; Ray, S; Rossebø, AB; Skjaerpe, T; Wachtell, K; Willenheimer, R | 1 |
| Fleming, TR | 1 |
| Robinson, JG | 1 |
| Fee, WH | 1 |
| Porat, G | 1 |
| Fleg, JL; Galloway, JM; Henderson, JA; Howard, BV; Howard, WJ; Mete, M; Ratner, RE; Roman, MJ; Silverman, A; Stylianou, M; Umans, JG; Weir, MR; Wilson, C | 1 |
| Stein, EA | 1 |
| Pazianas, M | 1 |
| Avis, HJ; Hutten, BA; Kastelein, JJ; Vissers, MN; Wijburg, FA | 1 |
| Chambers, JB; Viljoen, A; Wierzbicki, AS | 1 |
| Carabello, BA | 1 |
| Flameng, W; Herijgers, P; Hermans, H; Herregods, MC; Holvoet, P; Meuris, B; Verbeken, E | 1 |
| Boman, K; Brudi, P; Egstrup, K; Gohlke-Baerwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Pedersen, TR; Rossebø, AB; Wachtell, K; Willenheimer, R | 1 |
| Lester, SJ; Mookadam, F; Moustafa, SE; Warsame, T | 1 |
| Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Nienaber, C; Pedersen, TR; Ray, S; Rossebø, AB; Skjærpe, T; Wachtell, K; Willenheimer, R | 1 |
| Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Jander, N; Kesäniemi, YA; Malbecq, W; Minners, J; Neumann, FJ; Nienaber, CA; Pedersen, TR; Ray, S; Rossebø, A; Skjærpe, T; Wachtell, K; Willenheimer, R | 1 |
| Aschermann, M; Downe, RW; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Martasek, P; Mintz, GS; Mrazek, V; Skalicka, H; Skulec, R; Sonka, M; Uhrova, J; Wahle, A | 1 |
| Stanek, EJ; Taylor, AJ; Villines, TC | 1 |
| Coakley, J; Forbes, DA; Martin, AC; Sullivan, DR; Watts, GF | 1 |
| Patel, SB | 1 |
| Alemao, E; Cook, JR; Drummond, M; Yin, D | 1 |
| Allen, C; Boman, K; Chambers, J; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Kesäniemi, VA; Malbecq, W; Nienaber, C; Pedersen, TR; Ray, S; Rossebø, AB; Skjaerpe, T; Wachtell, K; Willenheimer, R | 1 |
| Padial, LR | 1 |
| Compton, DS; Davis, HR; Hoos, L; Tetzloff, G | 1 |
11 review(s) available for ezetimibe and Disease Exacerbation
| Article | Year |
|---|---|
Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Anticholesteremic Agents; Atherosclerosis; Bile Acids and Salts; Cholesterol, LDL; Disease Progression; Ezetimibe; Genetic Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Intestinal Mucosa; MicroRNAs; Mutation; PCSK9 Inhibitors; Proprotein Convertase 9; Receptors, LDL; RNA, Small Interfering; Sequestering Agents | 2018 |
Natural history of mild and of moderate aortic stenosis-new insights from a large prospective European study.
Topics: Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Azetidines; Calcinosis; Comorbidity; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypertension; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Simvastatin; Treatment Outcome | 2013 |
Non-cholesterol sterols and cholesterol metabolism in sitosterolemia.
Topics: Absorption; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G; ATP-Binding Cassette Transporters; Azetidines; Cholesterol; Disease Progression; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Diseases; Kinetics; Lipid Metabolism, Inborn Errors; Membrane Proteins; Membrane Transport Proteins; Phytosterols; Sitosterols; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sterols; Xanthomatosis | 2013 |
Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 Like 1 [NPC1L1).
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol; Cholesterol, Dietary; Disease Progression; Ezetimibe; Humans; Intestinal Absorption; Intestinal Mucosa | 2008 |
LDL reduction: how low should we go and is it safe?
Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Muscular Diseases; Niacin; Risk Factors; Stroke | 2008 |
The use of lipid-lowering drug therapy in children and adolescents.
Topics: Adolescent; Atherosclerosis; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Cholesterol; Clofibric Acid; Disease Progression; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ion Exchange Resins; Niacin; Practice Guidelines as Topic; Treatment Outcome | 2009 |
Aortic stenosis and lipids: does intervention work?
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Biomarkers, Pharmacological; Calcinosis; Disease Progression; Endothelium, Vascular; Ezetimibe; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Simvastatin; Stress, Physiological | 2010 |
Statins for calcific aortic valve stenosis: into oblivion after SALTIRE and SEAS? An extensive review from bench to bedside.
Topics: Animals; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Azetidines; Calcinosis; Disease Progression; Endothelium, Vascular; Ezetimibe; Heart Valve Prosthesis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Oxidative Stress; Randomized Controlled Trials as Topic | 2010 |
Subclinical atherosclerosis: evolving role of carotid intima-media thickness.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Ezetimibe; Humans; Prognosis; Risk Factors; Tunica Intima; Tunica Media | 2010 |
Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, Dietary; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption | 2004 |
Ezetimibe plus simvastatin cardiovascular outcomes study program.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Simvastatin; Treatment Outcome | 2008 |
23 trial(s) available for ezetimibe and Disease Exacerbation
| Article | Year |
|---|---|
Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Asymptomatic Diseases; Biomarkers; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Echocardiography, Doppler; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Simvastatin; Time Factors; Treatment Outcome | 2019 |
Higher Acceleration/Ejection Time Ratio Predicts Impaired Outcome in Aortic Valve Stenosis.
Topics: Aged; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Disease Progression; Double-Blind Method; Echocardiography; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prognosis; Prospective Studies; Severity of Illness Index; Simvastatin; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2021 |
Impact of stroke volume on cardiovascular risk during progression of aortic valve stenosis.
Topics: Aged; Anticholesteremic Agents; Aortic Valve Stenosis; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Ezetimibe; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Norway; Prognosis; Prospective Studies; Risk Factors; Simvastatin; Stroke Volume; Survival Rate; Sweden; Ventricular Function, Left | 2017 |
Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, LDL; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Quinolines; Ultrasonography, Interventional | 2018 |
Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Disease Progression; Double-Blind Method; Drug Combinations; Echocardiography, Doppler; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin; Survival Rate; Treatment Outcome | 2018 |
Effect of simvastatin and ezetimibe on suPAR levels and outcomes.
Topics: Aged; Anticholesteremic Agents; Aorta; Aortic Valve Stenosis; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Constriction, Pathologic; Disease Progression; Ezetimibe; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Receptors, Urokinase Plasminogen Activator; Risk Factors; Simvastatin | 2018 |
Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Vessels; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Tomography, Optical Coherence | 2014 |
Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Canada; Cholesterol; Disease Progression; Dose-Response Relationship, Drug; Drug Costs; Drug Prescriptions; Ezetimibe; Follow-Up Studies; Humans; Hypercholesterolemia; Prevalence; Retrospective Studies; Time Factors; Treatment Outcome; United States | 2014 |
Effects of lowering LDL cholesterol on progression of kidney disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Renal Dialysis; Simvastatin; Treatment Outcome | 2014 |
Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Neoplasms; Registries; Retrospective Studies; Risk Assessment; Simvastatin; Survival Rate; Time Factors | 2014 |
Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD.
Topics: Aged; Anticholesteremic Agents; Disease Progression; Educational Status; Ezetimibe; Female; Humans; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Severity of Illness Index; Simvastatin; Vascular Diseases | 2016 |
Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Treatment Outcome; Ultrasonography, Interventional | 2016 |
Pathologic Intimal Thickening Plaque Phenotype: Not as Innocent as Previously Thought. A Serial 3D Intravascular Ultrasound Virtual Histology Study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Plaque, Atherosclerotic; Severity of Illness Index; Time Factors; Ultrasonography, Interventional; User-Computer Interface | 2017 |
Effects of ezetimibe and anticoagulant combined therapy on progressing stroke: a randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Anticoagulants; Cholesterol; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Humans; Imaging, Three-Dimensional; Interleukin-6; Male; Matrix Metalloproteinase 9; Middle Aged; Retrospective Studies; Stroke; Treatment Outcome; Ultrasonography | 2016 |
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticholesteremic Agents; Aortic Valve Stenosis; Aspartate Aminotransferases; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Bypass; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Kaplan-Meier Estimate; Male; Neoplasms; Simvastatin; Treatment Outcome | 2008 |
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Tunica Intima; Tunica Media | 2008 |
The SEAS Trial.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2010 |
Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Apolipoproteins B; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography, Doppler; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Prognosis; Simvastatin; Time Factors | 2010 |
Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).
Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Azetidines; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography; Ezetimibe; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Simvastatin; Treatment Outcome | 2010 |
Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction.
Topics: Aged; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Electrocardiography; Ezetimibe; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Prospective Studies; Retrospective Studies; Severity of Illness Index; Simvastatin; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2011 |
Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Adhesion Molecules; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Ezetimibe; Female; Humans; Male; Risk Factors | 2012 |
Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Blood Flow Velocity; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Europe; Ezetimibe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Simvastatin; Stroke Volume; Treatment Outcome; Triglycerides; Ventricular Function, Left | 2007 |
13 other study(ies) available for ezetimibe and Disease Exacerbation
| Article | Year |
|---|---|
Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia.
Topics: Animals; Aspirin; Chemoprevention; Cholecystolithiasis; Cholesterol; Cholesterol, Dietary; Chronic Disease; Diet; Disease Models, Animal; Disease Progression; Ezetimibe; Fatty Liver; Feeding Behavior; Gallbladder Neoplasms; Gallstones; Inflammation; Male; Metaplasia; Mice, Inbred C57BL; Precancerous Conditions; Spleen | 2020 |
Impact of intensively lowered low-density lipoprotein cholesterol on deferred lesion prognosis.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Down-Regulation; Dyslipidemias; Ezetimibe; Female; Fractional Flow Reserve, Myocardial; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Time-to-Treatment; Treatment Outcome | 2020 |
Effects of simvastatin, ezetimibe, and their combination on histopathologic alterations caused by adjuvant-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Arthritis; Azetidines; Cartilage, Articular; Disease Progression; Drug Therapy, Combination; Ezetimibe; Flow Cytometry; Freund's Adjuvant; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Rats; Simvastatin; Tumor Necrosis Factor-alpha | 2014 |
Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Clinical Trials as Topic; Disease Progression; Ezetimibe; Female; Humans; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Middle Aged; Retrospective Studies; Simvastatin; Treatment Outcome; United States | 2014 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Identifying and addressing safety signals in clinical trials.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin | 2008 |
The ENHANCE trial.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2008 |
The ENHANCE trial.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2008 |
Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion?
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Carotid Arteries; Carotid Artery Diseases; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Tunica Intima; Tunica Media | 2008 |
Calcific aortic stenosis.
Topics: Animals; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Calcinosis; Disease Progression; Ezetimibe; Humans; Models, Biological; Renal Insufficiency, Chronic; Simvastatin | 2009 |
Familial hypercholesterolaemia in children and adolescents: a new paediatric model of care.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atherosclerosis; Azetidines; Child; Congenital Abnormalities; Coronary Stenosis; Disease Progression; Early Diagnosis; Ezetimibe; Female; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Standard of Care | 2013 |
Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Coronary Disease; Cost Control; Cost-Benefit Analysis; Disease Progression; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Models, Economic; Reproducibility of Results; Time Factors | 2004 |
Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Apolipoproteins E; Arteriosclerosis; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Diet, Fat-Restricted; Disease Progression; Ezetimibe; Intestinal Absorption; Lipoproteins; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Mutant Strains | 2001 |